NEWSLETTER

By clicking submit, you agree to share your email address with TFN to receive marketing, updates, and other emails from the site owner. Use the unsubscribe link in the emails to opt out at any time.

Carlsberg spinout Traitomic raises €20M from Sofinnova to sell non-GM traits beyond barley

Traitsource
Image credits: Traitomic
  • Danish Traitomic have raised €20M in a Series A round led by Sofinnova Partners.
  • Carlsberg retains ownership of FIND-IT’s IP, and Traitomic has an exclusive licence to use it outside brewing.
  • Traitomic is currently looking at around 100 traits with its customers before going to market.

When Carlsberg gave a small team a licence to use its FIND-IT screening tool outside the brewery, they came with one stipulation: don’t go near brewing. That’s the situation that Traitomic found itself in when they got the licence from Carlsberg.

The company has now raised €20M in Series A funding, led by Sofinnova Partners, to take its business forward within those constraints.

The Export and Investment Fund of Denmark, Footprint Firm, Nordic Foodtech VC, PSV Hafnium and SVG Ventures all joined the round. Traitomic have delivered 116 traits to 47 customers and is working across 32 different organisms, from crop improvement through to enzymes for industrial biotech.

Gustav Hambraeus, CEO and co-founder, told Tech Funding News the team is 30 people. According to Hambraeus, this is the first time Traitomic has raised money on its own, and the press release calls it the first external investment since the spinout.

Licensed, not owned

Carlsberg created FIND-IT and holds the IP, says Hambraeus. Traitomic has an exclusive licence for all uses other than brewing, and Carlsberg continues to use it for brewing. Hambraeus says it was launched in 2022.

Carlsberg is looking for external investment as Traitomic grows well beyond its brewing-group roots. “It’s like a little bit of a teenager. Now we need to move out,” Hambraeus said, adding that “we are not just two students sitting in a garage and trying to do this,” pointing to the Carlsberg research behind it.

Anders Røed, executive vice president group strategy and commercial at Carlsberg, added, “Traitomic is an excellent example of how fundamental research can create value far beyond its original field of application. FIND-IT was developed at Carlsberg Research Laboratory to improve barley, and it is now enabling advances in agriculture, food production and industrial biotechnology. I am proud of what the team has achieved and excited to continue supporting the company as it enters this next phase of international growth.”

How fast, and how many reach market

FIND-IT screens conventional breeding populations for a particular genetic change. Carlsberg scientists described it in Science Advances in 2022, using a library of 500,000 barley plants.

Hambraeus says that for a plant that Traitomic already has a platform for, a trait takes one to two months. For a crop it’s never worked with before, it takes one seed-to-seed cycle. Meanwhile, for bacteria, it takes about a week to set up.

Traitomic works with both plants and microbes. The customers get the traits integrated into their own elite varieties or production strains, which he calls “market-ready traits.” So a plant breeder might, for instance, have a variety that they’ve had for decades.

“We have 100 traits in pre-commercial assessment with our clients,nd I’m extremely excited to see how much of that actually goes to market,” noted Hambraeus.

The open question is how many of the 116 delivered traits reach a field or a fermenter. The EU passed rules in June 2026 that will facilitate the regulation of a number of gene-edited plants, with most changes coming into effect in July 2028.

Competitors in the space, like Tropic and Rainbow Crops, are all using gene editing. The regulatory regime could erode Traitomic’s current advantage. Hambraeus sees the other trait developers as peers in the new industry rather than as competitors.

Where the money goes

The company is also looking to broaden its scope. Traitomic make a distinction between trait discovery and development within the customer’s own organism. “We were potentially a find it company before and now we’re becoming a little bit more of an end-to-end [trait] development company,” Hambraeus says. Next organisms could include mushrooms, algae and probiotic bacteria.

Michael Krel, partner at Sofinnova, who also led IMIO’s $12 million crop microbes round, said: “Traitomic has demonstrated something that is rare in biological innovation: the ability to develop commercially relevant traits across a broad range of organisms and applications. Combined with the company’s strong customer traction and proven track record, this creates a compelling foundation for future growth.”

Hambraeus says the money will be primarily used to grow the business. Customers are in Europe, the US, Australia, SE Asia and East Asia. The US and Australia are the first priorities with local teams and an Australian branch focused on plant trait development.

Total
0
Shares
Related Posts
Total
0
Share
tfn-logo-2-220x220-removebg-preview

Get daily funding news briefings in the tech world delivered right to your inbox.

Enter Your Email
join our newsletter. thank you
TFN Banner